View Older Stories View More Recent Stories
-
Pfizer's BRAFTOVI shows improved survival in colorectal cancer trial
-
Bernstein Reiterates Market Perform Rating on Pfizer (PFE)
-
Pfizer (PFE) PT Lowered to $33 at Freedom Capital Markets
-
Pfizer (PFE) Launches Cost Savings Program on TrumpRx
-
Pfizer (PFE) Tops Q4 EPS by 8c, Beats on Revenue; Offers FY26 Guidance
-
Pfizer obesity drug shows 12.3% weight loss in phase 2b trial
-
Pfizer earnings preview Q4: softer print expected, drug pipeline in focus
-
Pfizer (PFE) call put ratio 2.2 calls to 1 put into quarter results
-
Pfizer (PFE) call put ratio 3.3 calls to 1 put into quarter results
-
Pfizer (PFE) call put ratio 2.5 calls to 1 put into quarter results
-
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks
-
Goldman Sachs Previews Pfizer (PFE) Earnings
-
Bernstein Reiterates Market Perform Rating on Pfizer (PFE)
-
Shionogi Invests $2.1 bln To Raise Stake in Viiv Healthcare - Bloomberg
-
Pfizer (PFE) CEO: to launch next-gen obesity assets acquired through Metsera buyout in 2028 - JPM Conference
-
Pfizer's BRAFTOVI shows improved response rates in colorectal cancer trial
-
Pfizer (PFE) call put ratio 1.2 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
UBS Assumes Pfizer (PFE) at Neutral
-
FDA revokes emergency use authorizations (EMAs) issued to Pfizer for lucira by Pfizer Covid-19 & flu test
-
Drugmakers Raise Us Prices On 350 Medicines Despite Pressure From Trump - Reuters
-
TD Cowen Reiterates Hold Rating on Pfizer (PFE)
-
Pfizer: does not anticipate any impact to safety for patients treated with approved marstacimab
-
Patient Dies After Taking Pfizer’s Drug for Blood Disorder
-
Trump to announce prescription drug price agreements
-
BMO Capital on Pfizer (PFE): 'Conservative Guide Sets the Stage for 2026 Post Metsera'
-
Bernstein Reiterates Market Perform Rating on Pfizer (PFE)
-
PADCEV-Keytruda combo shows survival benefit in bladder cancer trial
-
Guggenheim Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) PT Lowered to $24 at Wolfe Research
-
Pfizer (PFE) PT Lowered to $27 at BofA Securities
-
Pfizer provides 2026 financial guidance with lower revenue and earnings outlook
-
Adaptive Biotechnologies signs two TCR licensing deals with Pfizer
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.6% Yield
-
FDA may add black box warning to Covid-19 vaccines, CNN says
-
BMO Capital on Pfizer (PFE): 'Results are positive for tucatinib commercial expansion'
-
Pfizer's TUKYSA extends progression-free survival in breast cancer trial
-
FDA probe of alleged deaths tied to Covid shots includes adults
-
FDA Probe Of Alleged Deaths Tied To Covid Shots Includes Adults
-
Guggenheim Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer's HYMPAVZI shows 93% bleed reduction in hemophilia trial
-
Citi Resumes Pfizer (PFE) at Neutral
-
Shares of vaccine makers drop after FDA memo flags reports of child deaths
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
Bernstein on IRA pricing: $245 really is the floor
-
Pfizer (PFE) 35K contracts of December 25.50 calls trade
-
Arvinas to present vepdegestrant data at breast cancer symposium
-
Pfizer (PFE) PT Raised to $35 at Guggenheim
-
FDA approves Padcev plus Keytruda for certain patients with bladder cancer
-
FDA approves Keytruda and Padcev combo for bladder cancer treatment
-
Popular stocks with increasing volume: PLTR MSTR SOFI ORCL BABA CRWV MU HOOD INTC PFE
